Skip to main content
. 2013 May 9;1(4):685–691. doi: 10.3892/mco.2013.113

Table II.

Treatment response following concurrent chemoradiotherapy.

Variable Patient no.a (%)
Primary tumour (n=31)
  CR 23 (74.2)
  PR 7 (22.6)
  SD 1 (3.2)
Lymph node metastasis (n=26)
  CR 18 (69.2)
  PR 7 (26.9)
  SD 1 (3.9)
Primary tumour + lymph node (n=31)
  CR 19 (61.3)
  PR 11 (35.5)
  SD 1 (3.2)
a

Total patient no. was 31. DFS, disease-free survival.